Marjorie Schlecht
Physician Assistant · Chickasha, OKNPI 1649320334
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 761 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $4,362 and has fallen 99.6% since, to $17 in 2025. Among physician assistant clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 761 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- Johnson & Johnson$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$991
- plus $6K from 18 others
What the payments were for
- Food & beverage$13,41299%
- Education$1141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 110 | $2,224 |
| Otsuka America Pharmaceutical, Inc. | 77 | $1,305 |
| Vanda Pharmaceuticals Inc. | 52 | $1,273 |
| Johnson & Johnson | 72 | $1,155 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 77 | $1,040 |
| AbbVie | 89 | $991 |
| Alkermes, Inc. | 37 | $887 |
| Lundbeck LLC | 43 | $851 |
| Corium, LLC | 20 | $527 |
| Neurocrine Biosciences, Inc. | 49 | $453 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $440 |
| Sunovion Pharmaceuticals Inc. | 21 | $414 |
| Supernus Pharmaceuticals, Inc. | 10 | $398 |
| Indivior Inc. | 13 | $228 |
| Ironshore Pharmaceuticals Inc. | 10 | $219 |
| Axsome Therapeutics, Inc. | 9 | $208 |
| Bausch Health US, LLC | 13 | $202 |
| Almatica Pharma LLC | 9 | $181 |
| Merck | 9 | $151 |
| Noven Pharmaceuticals, Inc. | 1 | $108 |
| Noven Therapeutics, LLC | 7 | $107 |
| Idorsia Pharmaceuticals US Inc | 5 | $90 |
| Eisai Inc. | 3 | $54 |
| Tris Pharma Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$467
- QELBREE$205
- INVEGA SUSTENNA$128
- Azstarys$125
- ABILIFY MAINTENA$124
- SPRAVATO$122
- Austedo XR$120
- CAPLYTA$118
- REXULTI$117
- AUSTEDO$117
- Xelstrym$108
- UZEDY$101
How this compares
$13,526 in reported general payments places this provider in the 95th percentile of 1,491 physician assistant providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 37 | $238,634 |
| VraylarCariprazine Hcl | 66 | $95,888 |
| RexultiBrexpiprazole | 43 | $72,443 |
| Invega SustennaPaliperidone Palmitate | 19 | $54,826 |
| AristadaAripiprazole Lauroxil | 13 | $32,695 |
| BelsomraSuvorexant | 36 | $15,621 |
| Lurasidone Hcl | 46 | $12,174 |
| Aripiprazole | 256 | $10,002 |
| QuviviqDaridorexant Hcl | 16 | $7,786 |
| Duloxetine Hcl | 289 | $5,546 |
| Quetiapine Fumarate | 223 | $3,700 |
| Bupropion XlBupropion Hcl | 213 | $3,414 |
| Buspirone Hcl | 177 | $2,424 |
| Olanzapine | 85 | $2,399 |
| Divalproex Sodium | 41 | $2,173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $2,224 | $238,63437 claims |
| AbbVieVraylar | $991 | $95,88866 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,305 | $72,44343 claims |
| Johnson & JohnsonInvega Sustenna | $1,155 | $54,82619 claims |
| Alkermes, Inc.Aristada | $887 | $32,69513 claims |
| MerckBelsomra | $151 | $15,62136 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $90 | $7,78616 claims |
| Almatica Pharma LLCSertraline Hcl | $181 | $1,038189 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,491 physician assistant providers in Oklahoma.
Other physician assistant in Chickasha
- Eric CampbellEdmond$246K
- Jennifer SmithOklahoma City$134K
- Christy NiehuesMustang$28K
- Matthew PattonTulsa$24K
- Sarah HawkOklahoma City$23K
- Gavin ChristieEdmond$19K
- Michelle GreenTulsa$18K
- Muge ParkTulsa$17K
- Rose RamirezTulsa$15K
- Melissa RohrerTulsa$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.